Gene · 92521
Papers3,158
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
601 to 620 of 3,158
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
Repurposing FDA-approved drugs cetilistat, abiraterone, diiodohydroxyquinoline, bexarotene, and remdesivir as potential inhibitors against RNA dependent RNA polymerase of SARS-CoV-2: A comparative in silico perspective. | Inform Med Unlocked | 2023 | 36510496 | PubTator, text mining | PubMed |
| pH profiles of 3-chymotrypsin-like protease (3CLpro) from SARS-CoV-2 elucidate its catalytic mechanism and a histidine residue critical for activity. | J Biol Chem | 2023 | 36509143 | PubTator, text mining | PubMed |
| Genome Sequences of SARS-CoV-2 Strains from the Republic of Moldova. | Microbiol Resour Announc | 2023 | 36507680 | PubTator, text mining | PubMed |
| Insights from incorporating quantum computing into drug design workflows. | Bioinformatics | 2023 | 36477833 | PubTator, text mining | PubMed |
| Glycyrrhizin as a promising kryptonite against SARS-CoV-2: Clinical, experimental, and theoretical evidences. | J Mol Struct | 2023 | 36467615 | PubTator, text mining | PubMed |
| A review on structural, non-structural, and accessory proteins of SARS-CoV-2: Highlighting drug target sites. | Immunobiology | 2023 | 36434912 | PubTator, text mining | PubMed |
| A common variant close to the "tripwire" linker region of NLRP1 contributes to severe COVID-19. | Inflamm Res | 2023 | 36416944 | PubTator, text mining | PubMed |
| Peptide Amphiphile Mediated Co-assembly for Nanoplasmonic Sensing. | Angew Chem Int Ed Engl | 2023 | 36409652 | PubTator, text mining | PubMed |
| Novel ciprofloxacin and norfloxacin-tetrazole hybrids as potential antibacterial and antiviral agents: Targeting S. aureus topoisomerase and SARS-CoV-2-MPro. | J Mol Struct | 2023 | 36406777 | PubTator, text mining | PubMed |
| Masitinib analogues with the N-methylpiperazine group replaced - A new hope for the development of anti-COVID-19 drugs. | J King Saud Univ Sci | 2023 | 36406239 | PubTator, text mining | PubMed |
| GPR183 antagonism reduces macrophage infiltration in influenza and SARS-CoV-2 infection. | Eur Respir J | 2023 | 36396144 | PubTator, text mining | PubMed |
| Mutations in SARS-CoV-2: Insights on structure, variants, vaccines, and biomedical interventions. | Biomed Pharmacother | 2023 | 36370519 | PubTator, text mining | PubMed |
| The efficacy of Paxlovid against COVID-19 is the result of the tight molecular docking between Mpro and antiviral drugs (nirmatrelvir and ritonavir). | Adv Med Sci | 2023 | 36368287 | PubTator, text mining | PubMed |
| Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir. | Nature | 2023 | 36351451 | PubTator, text mining | PubMed |
| Real-Time Whole Genome Sequencing to Guide Patient-Tailored Therapy of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. | Clin Infect Dis | 2023 | 36327795 | PubTator, text mining | PubMed |
| S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters. | Sci Transl Med | 2023 | 36327352 | PubTator, text mining | PubMed |
| COVID-19 signalome: Pathways for SARS-CoV-2 infection and impact on COVID-19 associated comorbidity. | Cell Signal | 2023 | 36252792 | PubTator, text mining | PubMed |
| A comprehensive SARS-CoV-2-human protein-protein interactome reveals COVID-19 pathobiology and potential host therapeutic targets. | Nat Biotechnol | 2023 | 36217030 | PubTator, text mining | PubMed |
| TRIM67 drives tumorigenesis in oligodendrogliomas through Rho GTPase-dependent membrane blebbing. | Neuro Oncol | 2023 | 36215168 | PubTator, text mining | PubMed |
| SARS-CoV-2 mediated dysregulation in cell signaling events drives the severity of COVID-19. | Virus Res | 2023 | 36209917 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/92521/papers?page=31